Dr William Leonard Yingling, MD | |
307 E. New Market St., 307 E. New Market St., Freeburg, PA 17827-0243 | |
(570) 374-9533 | |
Not Available |
Full Name | Dr William Leonard Yingling |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 307 E. New Market St., Freeburg, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801049242 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD013678E (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr William Leonard Yingling, MD Po Box 243, 307 E. New Market St., Freeburg, PA 17827-0243 Ph: (570) 374-9533 | Dr William Leonard Yingling, MD 307 E. New Market St., 307 E. New Market St., Freeburg, PA 17827-0243 Ph: (570) 374-9533 |
News Archive
Congress passed major health-related legislation in time for the fiscal year, which began Monday, including a broad bill to address the opioid epidemic and a spending bill for the Department of Health and Human Services.
The drafty backside is finally gone, replaced with comfort, warmth and dignity in a newly designed hospital gown that blends style for the patient with clinical function for the health care team.
The new study analyses data from school aged children in Tanzania infected with the most common forms of worms. It was found that infection by one parasitic species actually changes the risk of catching another, over and above other risk factors.
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.
› Verified 1 days ago